Drugs · acquisition-cost intelligence
ciclopirox
· ingredient ciclopiroxOther antifungals for topical use· CICLOPIROX 7.7 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.88316
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other ciclopirox products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| ciclopirox olamine | $0.18367 | −$0.69950 |
| ciclopirox | $0.26404 | −$0.61910 |
| Ciclopirox Olamine | $0.55004 | −$0.33310 |
| ciclopirox | $1.34 | +$0.45820 |
Medicare Part D coverage · CY2026
On 195 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 49% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.